CG Oncology, Inc. (CGON) stock
CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$80.00+1.06 (+1.34%)
Close on Nov 18, 2026Market cap $7.09BP/E –Yield –
CG Oncology free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
CG Oncology's free cash flow for the twelve months ending Sep 30, 2026 was -$189.17M. For fiscal 2025 it was -$132.48M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$132.48M | – |
| FY2024 | Dec 31, 2024 | -$78.95M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$48.82M | – |
| Q2 FY2026 | Jun 30, 2026 | -$46.88M | – |
| Q1 FY2026 | Mar 31, 2026 | -$57.25M | – |
| Q4 FY2025 | Dec 31, 2025 | -$36.22M | – |
| Q3 FY2025 | Sep 30, 2025 | -$38.99M | – |
| Q2 FY2025 | Jun 30, 2025 | -$27.97M | – |
| Q1 FY2025 | Mar 31, 2025 | -$29.29M | – |
| Q4 FY2024 | Dec 31, 2024 | -$20.87M | – |
| Q3 FY2024 | Sep 30, 2024 | -$15.92M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.13M | – |
| Q1 FY2024 | Mar 31, 2024 | -$26.02M | – |
See a number that looks wrong?